GSK Investigational Site

Statesville, North Carolina 28677

0 studies enrolling now · 21 studies all time

What they study most

Arthritis, Rheumatoid, Asthma, Atherosclerosis, Diabetes Mellitus, Dyslipidaemias, Dyslipidemias, Fibrillation, Atrial, Hypertension, Hypertriglyceridemia, Pulmonary Disease, Chronic Obstructive, Respiratory Syncytial Virus Infections

Studies at this site

• Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above — Completed
• Study to Test GSK256073 in Patients With Dyslipidemia — Completed
• Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus — Completed
• A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension — Completed
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study — Completed
• Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects — Completed
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial — Completed
• COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis — Completed
• Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation — Completed
• A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD). — Completed
• Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) — Completed
• ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. — Completed
• GSK BHR Study (Sont) — Completed
• SB-480848 In Subjects With Coronary Heart Disease — Completed
• Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension — Completed
• Dyslipidemia Study Investigating The Increase In "Good Cholesterol" — Completed
• A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™ — Completed